DOP2021000088A - Compuestos de azalactam como inhibidores de hpk1 - Google Patents
Compuestos de azalactam como inhibidores de hpk1Info
- Publication number
- DOP2021000088A DOP2021000088A DO2021000088A DO2021000088A DOP2021000088A DO P2021000088 A DOP2021000088 A DO P2021000088A DO 2021000088 A DO2021000088 A DO 2021000088A DO 2021000088 A DO2021000088 A DO 2021000088A DO P2021000088 A DOP2021000088 A DO P2021000088A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- azalactam
- pharmaceutically acceptable
- acceptable salts
- hpk1 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R1a, R2, R3, R4, y (R5)a son como se definen en la presente, a composiciones farmacéuticas que comprenden dichos compuestos y sales de estos aceptables desde el punto de vista farmacéutico, y a métodos de uso de dichos compuestos, sales de estos aceptables desde el punto de vista farmacéutico y composiciones para el tratamiento del crecimiento anormal de células, que incluye cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767602P | 2018-11-15 | 2018-11-15 | |
| US201962909970P | 2019-10-03 | 2019-10-03 | |
| PCT/IB2019/059702 WO2020100027A1 (en) | 2018-11-15 | 2019-11-12 | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000088A true DOP2021000088A (es) | 2021-06-30 |
Family
ID=68771726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000088A DOP2021000088A (es) | 2018-11-15 | 2021-05-07 | Compuestos de azalactam como inhibidores de hpk1 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US11142525B2 (es) |
| EP (1) | EP3880676B1 (es) |
| JP (1) | JP7118267B2 (es) |
| KR (1) | KR20210090675A (es) |
| CN (1) | CN113316576A (es) |
| AU (1) | AU2019378184B2 (es) |
| BR (1) | BR112021008991A2 (es) |
| CA (1) | CA3061392A1 (es) |
| CL (1) | CL2021001190A1 (es) |
| CO (1) | CO2021006114A2 (es) |
| CR (1) | CR20210251A (es) |
| CU (1) | CU20210035A7 (es) |
| DK (1) | DK3880676T3 (es) |
| DO (1) | DOP2021000088A (es) |
| EC (1) | ECSP21034668A (es) |
| ES (1) | ES2958948T3 (es) |
| FI (1) | FI3880676T3 (es) |
| GE (1) | GEP20227434B (es) |
| HR (1) | HRP20231089T1 (es) |
| HU (1) | HUE063367T2 (es) |
| IL (1) | IL283149A (es) |
| LT (1) | LT3880676T (es) |
| MD (1) | MD3880676T2 (es) |
| MX (1) | MX2021005754A (es) |
| PE (1) | PE20211868A1 (es) |
| PH (1) | PH12021551117A1 (es) |
| PL (1) | PL3880676T3 (es) |
| PT (1) | PT3880676T (es) |
| RS (1) | RS64655B1 (es) |
| SG (1) | SG11202104394XA (es) |
| SI (1) | SI3880676T1 (es) |
| TW (1) | TWI718758B (es) |
| UA (1) | UA127426C2 (es) |
| UY (1) | UY38471A (es) |
| WO (1) | WO2020100027A1 (es) |
| ZA (1) | ZA202103099B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3181415A1 (en) * | 2020-05-01 | 2021-11-04 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
| CN112409268A (zh) * | 2020-12-03 | 2021-02-26 | 西南交通大学 | 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用 |
| CN117460732A (zh) * | 2021-06-11 | 2024-01-26 | 杭州中美华东制药有限公司 | 吡咯并吡啶酮类化合物及其制备方法和用途 |
| TW202321239A (zh) | 2021-07-20 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺 |
| WO2023023942A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same |
| CN118103369A (zh) * | 2021-09-03 | 2024-05-28 | 浙江海正药业股份有限公司 | 吡啶并内酰胺类衍生物及其制备方法和用途 |
| WO2023057883A1 (en) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Crystalline form of azalactam compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5243049A (en) * | 1992-01-22 | 1993-09-07 | Neurogen Corporation | Certain pyrroloquinolinones: a new class of GABA brain receptor ligands |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| BRPI0814441A2 (pt) * | 2007-07-19 | 2015-07-14 | Schering Corp | Compostos de amida heterocíclica como inibidores de proteína cinase |
| WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| JP7132937B2 (ja) | 2017-03-15 | 2022-09-07 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１の阻害剤としてのアザインドール |
| CN109265443B (zh) | 2017-07-18 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
| WO2019148005A1 (en) | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
-
2019
- 2019-11-11 US US16/679,820 patent/US11142525B2/en active Active
- 2019-11-12 WO PCT/IB2019/059702 patent/WO2020100027A1/en active Application Filing
- 2019-11-12 MD MDE20210902T patent/MD3880676T2/ro unknown
- 2019-11-12 FI FIEP19813943.8T patent/FI3880676T3/fi active
- 2019-11-12 RS RS20230847A patent/RS64655B1/sr unknown
- 2019-11-12 PT PT198139438T patent/PT3880676T/pt unknown
- 2019-11-12 PE PE2021000685A patent/PE20211868A1/es unknown
- 2019-11-12 ES ES19813943T patent/ES2958948T3/es active Active
- 2019-11-12 PL PL19813943.8T patent/PL3880676T3/pl unknown
- 2019-11-12 CR CR20210251A patent/CR20210251A/es unknown
- 2019-11-12 CU CU2021000035A patent/CU20210035A7/es unknown
- 2019-11-12 GE GEAP201915630A patent/GEP20227434B/en unknown
- 2019-11-12 SG SG11202104394XA patent/SG11202104394XA/en unknown
- 2019-11-12 BR BR112021008991-8A patent/BR112021008991A2/pt unknown
- 2019-11-12 LT LTEPPCT/IB2019/059702T patent/LT3880676T/lt unknown
- 2019-11-12 SI SI201930620T patent/SI3880676T1/sl unknown
- 2019-11-12 KR KR1020217017777A patent/KR20210090675A/ko active IP Right Grant
- 2019-11-12 UA UAA202102538A patent/UA127426C2/uk unknown
- 2019-11-12 HR HRP20231089TT patent/HRP20231089T1/hr unknown
- 2019-11-12 HU HUE19813943A patent/HUE063367T2/hu unknown
- 2019-11-12 JP JP2021525702A patent/JP7118267B2/ja active Active
- 2019-11-12 EP EP19813943.8A patent/EP3880676B1/en active Active
- 2019-11-12 AU AU2019378184A patent/AU2019378184B2/en active Active
- 2019-11-12 DK DK19813943.8T patent/DK3880676T3/da active
- 2019-11-12 CA CA3061392A patent/CA3061392A1/en active Pending
- 2019-11-12 CN CN201980089161.3A patent/CN113316576A/zh active Pending
- 2019-11-12 MX MX2021005754A patent/MX2021005754A/es unknown
- 2019-11-14 UY UY0001038471A patent/UY38471A/es unknown
- 2019-11-14 TW TW108141429A patent/TWI718758B/zh active
-
2021
- 2021-05-06 CL CL2021001190A patent/CL2021001190A1/es unknown
- 2021-05-07 ZA ZA2021/03099A patent/ZA202103099B/en unknown
- 2021-05-07 DO DO2021000088A patent/DOP2021000088A/es unknown
- 2021-05-11 CO CONC2021/0006114A patent/CO2021006114A2/es unknown
- 2021-05-12 IL IL283149A patent/IL283149A/en unknown
- 2021-05-14 EC ECSENADI202134668A patent/ECSP21034668A/es unknown
- 2021-05-14 PH PH12021551117A patent/PH12021551117A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000088A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| UY38553A (es) | Inhibidores de cdk2 | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| UY38196A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| UY35630A (es) | Carboxamidas primarias como inhibidores de btk | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| ECSP22084264A (es) | Compuestos de Azalactama como inhibidores de HPK1 | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| ECSP18056196A (es) | Derivados de indano | |
| DOP2016000326A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina |